000			01538 a2200421 4500
005			20250516005046.0
264		0	_c20110228
008			201102s 0 0 eng d
022			_a1872-9096
024	7		_a10.1016/j.antiviral.2010.10.001 _2doi
040			_aNLM _beng _cNLM
100	1		_aMyskiw, Chad
245	0	0	_aNigericin is a potent inhibitor of the early stage of vaccinia virus replication. _h[electronic resource]
260			_bAntiviral research _cDec 2010
300			_a304-10 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAntiviral Agents _xpharmacology
650	0	4	_aBioterrorism _xprevention & control
650	0	4	_aCarboxylic Acids _xpharmacology
650	0	4	_aGene Expression Regulation, Viral _xdrug effects
650	0	4	_aGreen Fluorescent Proteins _xanalysis
650	0	4	_aHeLa Cells
650	0	4	_aHumans
650	0	4	_aInhibitory Concentration 50
650	0	4	_aNigericin _xanalogs & derivatives
650	0	4	_aPoxviridae Infections _xdrug therapy
650	0	4	_aTime Factors
650	0	4	_aTranscription, Genetic _xdrug effects
650	0	4	_aVaccinia virus _xdrug effects
650	0	4	_aVirus Replication _xdrug effects
700	1		_aPiper, Jessica
700	1		_aHuzarewich, Rhiannon
700	1		_aBooth, Tim F
700	1		_aCao, Jingxin
700	1		_aHe, Runtao
773	0		_tAntiviral research _gvol. 88 _gno. 3 _gp. 304-10
856	4	0	_uhttps://doi.org/10.1016/j.antiviral.2010.10.001 _zAvailable from publisher's website
999			_c20255009 _d20255009